Reactions 1680, p60 - 2 Dec 2017 Various toxicities: 4 case reports In a single centre retrospective longitudinal observational study, four elderly patients [sexes and specific ages not stated] were described, who developed elevated serum AST and ALT levels (1 patient), fever and fatigue (1 patient), appetite loss and nausea (1 patient) and fatigue and dysphasia (1 patient) during treatment with daclatasvir and asunaprevir [times to reactions onsets and outcomes not stated]. All the patients had a history of chronic hepatitis C virus genotype 1b infection and liver dysfunction. Out of these four patients, three patients were included in chronic kidney disease (CKD) group, and the remaining patient was included in non-CKD group of the retrospective study. All the patients received antiviral therapy, which consisted of oral daclatasvir 60mg once daily after breakfast, and oral asunaprevir 100mg twice daily after breakfast and after supper. Various parameters including serum AST and ALT levels were routinely monitored. Subsequently, the patients developed elevated serum AST and ALT levels (n=1), fever and fatigue (n=1), appetite loss and nausea (n=1) and fatigue and dysphasia (n=1). The antiviral therapy was discontinued in all four patients. Author comment: "Adverse effects were comparable between the two groups." "The patients received oral administration of 60mg [daclatasvir] once a day after breakfast and 100mg [asunaprevir] twice a day". "Three patients in the CKD group withdrew the treatment due to the elevation in serum AST and ALT levels in 1 patient, fever and fatigue in 1, and appetite loss and nausea in 1". "[I]n the non-CKD group. . .fatigue and dysphasia in 1". Morisawa N, et al. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. Clinical and Experimental Nephrology 21: 818-824, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1007/s10157-016-1348-7 - Japan 803283897 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera